Clinical Relevance of Cell-free DNA in Gastrointestinal Tract Malignancy

Overview

Journal Oncotarget

Specialty Oncology

Date 2016 Dec 10

PMID 27936467

Citations 29

Authors

Yuan-Tzu Lan

Ming-Huang Chen

Wen-Liang Fang

Chih-Cheng Hsieh

Chien-Hsing Lin

Fang-Yu Jhang

Shung-Haur Yang

Jen-Kou Lin

Wei-Shone Chen

Jeng-Kai Jiang

Pei-Ching Lin

Shih-Ching Chang

Affiliations

Soon will be listed here.

Abstract

Background: Cell-free DNA (cfDNA) extracted from blood has become a clinically feasible biomarker in various types of cancer. However, the clinical significance of cfDNA in gastrointestinal (GI) tract cancer among Asian populations requires further investigation.

Results: The median cfDNA copy number was highest in esophageal cancer, followed by colorectal cancer and gastric cancer, which were all significantly higher than those of healthy individuals. The cfDNA levels were higher in GI tract cancer, followed by those in carcinoma in situ and then healthy individuals (P = 0.019). During the postoperative surveillance, the cfDNA level tended to be more sensitive than the carcinoembryonic antigen level in predicting recurrence. For recurrent gastric cancer, a persistently high cfDNA level and an increasing trend was observed after surgery. For stage IV colorectal cancer, dynamic changes in the cfDNA level were correlated with the responses to chemotherapy and surgery.

Materials And Methods: Blood samples were collected from 95 healthy individuals and from 855 patients diagnosed with GI tract malignancy, including 98 with esophageal cancer, 428 with stomach cancer, 329 with colorectal cancer and 30 with carcinoma in situ. The copy numbers of extracted cfDNA were analyzed and compared among the different types of GI cancers.

Conclusions: The cfDNA level can serve as a feasible biomarker for detecting tumors in GI tract cancer. The cfDNA level may play a role in predicting tumor responses to chemotherapy and surgery in colorectal cancer; tumor recurrence should be considered in gastric cancer with a persistently high cfDNA level after surgery.

Citing Articles

Liquid biopsy in cancer current: status, challenges and future prospects.

Ma L, Guo H, Zhao Y, Liu Z, Wang C, Bu J Signal Transduct Target Ther. 2024; 9(1):336.

PMID: 39617822 PMC: 11609310. DOI: 10.1038/s41392-024-02021-w.

Multi-dimensional cell-free DNA-based liquid biopsy for sensitive early detection of gastric cancer.

Yu P, Chen P, Wu M, Ding G, Bao H, Du Y Genome Med. 2024; 16(1):79.

PMID: 38849905 PMC: 11157707. DOI: 10.1186/s13073-024-01352-1.

Liquid biopsy for gastric cancer: Techniques, applications, and future directions.

Diaz Del Arco C, Fernandez Acenero M, Ortega Medina L World J Gastroenterol. 2024; 30(12):1680-1705.

PMID: 38617733 PMC: 11008373. DOI: 10.3748/wjg.v30.i12.1680.

Liquid Biopsy: An Emerging Diagnostic, Prognostic, and Predictive Tool in Gastric Cancer.

Han H, Lee K J Gastric Cancer. 2024; 24(1):4-28.

PMID: 38225764 PMC: 10774753. DOI: 10.5230/jgc.2024.24.e5.

Clinical applications and perspectives of circulating tumor DNA in gastric cancer.

Li J, Zhang D, Zhu J, Dong L Cancer Cell Int. 2024; 24(1):13.

PMID: 38184573 PMC: 10770949. DOI: 10.1186/s12935-024-03209-4.

References

Diehl F, Schmidt K, Choti M, Romans K, Goodman S, Li M . Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008; 14(9):985-90. PMC: 2820391. DOI: 10.1038/nm.1789. View

Openshaw M, Page K, Fernandez-Garcia D, Guttery D, Shaw J . The role of ctDNA detection and the potential of the liquid biopsy for breast cancer monitoring. Expert Rev Mol Diagn. 2016; 16(7):751-5. DOI: 10.1080/14737159.2016.1184974. View

Zachariah R, Schmid S, Radpour R, Buerki N, Fan A, Hahn S . Circulating cell-free DNA as a potential biomarker for minimal and mild endometriosis. Reprod Biomed Online. 2009; 18(3):407-11. DOI: 10.1016/s1472-6483(10)60100-9. View

Swystun L, Mukherjee S, Liaw P . Breast cancer chemotherapy induces the release of cell-free DNA, a novel procoagulant stimulus. J Thromb Haemost. 2011; 9(11):2313-21. DOI: 10.1111/j.1538-7836.2011.04465.x. View

Feng G, Ye X, Fang F, Pu C, Huang H, Li G . Quantification of plasma cell-free DNA in predicting therapeutic efficacy of sorafenib on metastatic clear cell renal cell carcinoma. Dis Markers. 2013; 34(2):105-11. PMC: 3810240. DOI: 10.3233/DMA-120950. View

Spindler K, Pallisgaard N, Vogelius I, Jakobsen A . Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res. 2012; 18(4):1177-85. DOI: 10.1158/1078-0432.CCR-11-0564. View

Qin Z, Ljubimov V, Zhou C, Tong Y, Liang J . Cell-free circulating tumor DNA in cancer. Chin J Cancer. 2016; 35:36. PMC: 4823888. DOI: 10.1186/s40880-016-0092-4. View

Goldstein M, Mitchell E . Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest. 2005; 23(4):338-51. DOI: 10.1081/cnv-58878. View

Stroun M, Maurice P, Vasioukhin V, Lyautey J, LEDERREY C, Lefort F . The origin and mechanism of circulating DNA. Ann N Y Acad Sci. 2000; 906:161-8. DOI: 10.1111/j.1749-6632.2000.tb06608.x. View

10.

Lin J, Lin P, Lin C, Jiang J, Yang S, Liang W . Clinical relevance of alterations in quantity and quality of plasma DNA in colorectal cancer patients: based on the mutation spectra detected in primary tumors. Ann Surg Oncol. 2014; 21 Suppl 4:S680-6. DOI: 10.1245/s10434-014-3804-5. View

11.

Taback B, Saha S, Hoon D . Comparative analysis of mesenteric and peripheral blood circulating tumor DNA in colorectal cancer patients. Ann N Y Acad Sci. 2006; 1075:197-203. DOI: 10.1196/annals.1368.027. View

12.

Thierry A, Mouliere F, El Messaoudi S, Mollevi C, Lopez-Crapez E, Rolet F . Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med. 2014; 20(4):430-5. DOI: 10.1038/nm.3511. View

13.

Sorbye H, Dahl O . Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to oxaliplatin combination chemotherapy: implications for tumor marker monitoring and guidelines. J Clin Oncol. 2003; 21(23):4466-7. DOI: 10.1200/JCO.2003.99.200. View

14.

Hao T, Shi W, Shen X, Qi J, Wu X, Wu Y . Circulating cell-free DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancer. Br J Cancer. 2014; 111(8):1482-9. PMC: 4200099. DOI: 10.1038/bjc.2014.470. View

15.

Bast Jr R, Ravdin P, Hayes D, Bates S, Fritsche Jr H, Jessup J . 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001; 19(6):1865-78. DOI: 10.1200/JCO.2001.19.6.1865. View

16.

Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A . Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007; 357(18):1810-20. DOI: 10.1056/NEJMoa072252. View

17.

Mori T, ODay S, Umetani N, Martinez S, Kitago M, Koyanagi K . Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. J Clin Oncol. 2005; 23(36):9351-8. PMC: 2856438. DOI: 10.1200/JCO.2005.02.9876. View

18.

Koyanagi K, Mori T, ODay S, Martinez S, Wang H, Hoon D . Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients. Cancer Res. 2006; 66(12):6111-7. PMC: 2856454. DOI: 10.1158/0008-5472.CAN-05-4198. View

19.

Steffensen K, Vestergaard Madsen C, Andersen R, Waldstrom M, Adimi P, Jakobsen A . Prognostic importance of cell-free DNA in chemotherapy resistant ovarian cancer treated with bevacizumab. Eur J Cancer. 2014; 50(15):2611-8. DOI: 10.1016/j.ejca.2014.06.022. View

20.

Fang W, Lan Y, Huang K, Liu C, Hung Y, Lin C . Clinical significance of circulating plasma DNA in gastric cancer. Int J Cancer. 2016; 138(12):2974-83. DOI: 10.1002/ijc.30018. View